Our Tests

TruGraf^® Kidney:

A gene expression profiling assay for ruling out “silent” rejection

TruGraf Kidney is the first and only non-invasive biomarker test approved for coverage and  validated for surveillance of stable kidney transplant recipients. With TruGraf Kidney, clinicians can rule out “silent” rejection early, allowing them to intervene before it becomes a more serious problem. Click here to learn more about how TruGraf Kidney can help you monitor kidney transplant health.

Learn More About How TruGraf Kidney Can Help You Monitor Kidney Transplant Health

Eurofins TRAC^® Kidney:

A donor-derived cell-free DNA assay for evaluating acute allograft rejection

The Eurofins TRAC (Transplant Rejection Allograft Check) donor-derived cell-free DNA assay is designed to utilize a noninvasive liquid biopsy to monitor the percentage of dd-cfDNA in transplant recipient plasma post-transplant using next generation sequencing (NGS). It utilizes a bioinformatics pipeline that analyzes NGS and genome-wide recipient genotype data to determine the percentage of dd-cfDNA present, which strongly correlates with allograft injury due to rejection. The licensed algorithm accurately quantifies the donor-derived fraction of cell-free DNA without need for donor genotype information, even when the donor is closely related (e.g., sibling kidney donors). 

Learn more about how Eurofins TRAC Kidney can help you monitor kidney transplant health

OmniGraf Liver:

A powerful combination of gene expression profiling and donor-derived cell-free DNA to guide titration of immunosuppression

OmniGraf Liver is the first product of its kind for liver transplant recipients. Clinicians can use this tool to rule out rejection in stable patients and ensure that steps taken to lower immunosuppressive therapy are effective at managing rejection, reducing the risk of complications later in life.